Adrenocortical carticnoma (ACC) is a rare malignancy with an incidence of 0.7–2.0
cases/million habitants/year. The diagnosis of malignancy relies on careful investigations of …

Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been
established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC) …

Adrenocortical carcinoma (ACC) is a rare and in most cases steroid hormone-producing
tumor with variable prognosis. The purpose of these guidelines is to provide clinicians with …

PD-1 Blockade in Advanced Adrenocortical Carcinoma - PMC Back to Top Skip to main content
NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …

Background Adrenocortical carcinoma is a rare, aggressive cancer for which few treatment
options are available. Linsitinib (OSI-906) is a potent, oral small molecule inhibitor of both …

Context Systemic treatment of metastatic adrenocortical carcinoma (ACC) remains limited to
chemotherapy and mitotane. Preliminary evidence suggesting that antitumor immune …

Origin of the adrenogonadal primordium The adrenal glands develop from 2 separate
embryologic tissues: the medulla is derived from neural crest cells originating in proximity to …

Context Although mitotane is the only approved drug for the treatment of adrenocortical
carcinoma (ACC), data on monotherapy in advanced disease are still scarce. Objective To …

The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is a key driver in carcinogenesis.
Defects in this pathway in human cancer syndromes such as Cowden's disease and Multiple …

The adrenal glands are paired endocrine organs that produce steroid hormones and
catecholamines required for life. Adrenocortical carcinoma (ACC) is a rare and often fatal …